CN111304176A - A large-scale purification method of adenovirus vector based on Q-6XL and 4FF - Google Patents
A large-scale purification method of adenovirus vector based on Q-6XL and 4FF Download PDFInfo
- Publication number
- CN111304176A CN111304176A CN202010154302.XA CN202010154302A CN111304176A CN 111304176 A CN111304176 A CN 111304176A CN 202010154302 A CN202010154302 A CN 202010154302A CN 111304176 A CN111304176 A CN 111304176A
- Authority
- CN
- China
- Prior art keywords
- adenovirus
- purification
- buffer
- virus
- chromatography
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10351—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
技术领域:Technical field:
本发明涉及腺病毒载体纯化领域,特别设计了基于Q-6XL和4FF串联的规模化腺病毒纯化方案。旨在提高腺病毒载体制备的效率和纯度,最终提高腺病毒制剂的产量和质量。The present invention relates to the field of adenovirus vector purification, and particularly designs a large-scale adenovirus purification scheme based on the tandem of Q-6XL and 4FF. It aims to improve the efficiency and purity of adenoviral vector preparation, and ultimately improve the yield and quality of adenoviral preparations.
背景技术:Background technique:
腺病毒在基因治疗方面有着巨大的潜力,其纯度、有效性、安全性有着严格的标准。 病毒与传统疫苗制剂不同,腺病毒与蛋白相比理化性质不同,并且需要在纯化过程中尽可 能的保持病毒活性。因此制备出满足用量的高纯度腺病毒,优化下游处理工艺是待解决的 关键性问题。Adenovirus has great potential in gene therapy, and its purity, efficacy, and safety have strict standards. Unlike traditional vaccine preparations, adenoviruses have different physicochemical properties than proteins, and it is necessary to maintain viral activity as much as possible during the purification process. Therefore, it is a key problem to be solved to prepare a high-purity adenovirus that meets the dosage and to optimize the downstream processing technology.
腺病毒载体的下游处理包括一系列旨在提高腺病毒载体制备的效率和纯度的步骤。其 中腺病毒的纯化工艺是提高最终病毒制剂产量和质量的关键。在过去10年中,病毒载体 的下游处理领域取得了相当大的进展。但是大部分研究工作都集中在广泛使用的疱疹病 毒、慢病毒等的纯化工艺。而腺病毒的纯化工艺研究较少,特别是满足用量需求的规模化 纯化工艺。腺病毒传统的纯化方法是CsCl(氯化铯)密度梯度离心法。该技术是采用高速 离心加强溶液的密度梯度,根据病毒与其他分子大小、形状和密度的差异将其从污染物中 进行分离。在离心过程中,病毒分子量较小位于溶液上层,其他污染物位于溶液下层。但这种纯化方法一般需要2-3轮重复离心才可获得较纯净的腺病毒颗粒,并且难以实现上下层溶液的彻底分离。因此这种方法获得的腺病毒产量低并且非常耗时的。因此,急需一种可以规模化生产出高纯度腺病毒载体的纯化方案。Downstream processing of adenoviral vectors includes a series of steps aimed at increasing the efficiency and purity of adenoviral vector preparation. Among them, the purification process of adenovirus is the key to improve the yield and quality of the final virus preparation. In the past 10 years, considerable progress has been made in the field of downstream processing of viral vectors. However, most of the research work has focused on the purification process of widely used herpes virus, lentivirus, etc. However, there are few studies on the purification process of adenovirus, especially the large-scale purification process that meets the dosage requirements. The traditional purification method of adenovirus is CsCl (cesium chloride) density gradient centrifugation. The technique uses high-speed centrifugation to enhance the density gradient of a solution, separating viruses from other molecules based on their differences in size, shape, and density from contaminants. During the centrifugation process, the virus with smaller molecular weight is located in the upper layer of the solution, and other contaminants are located in the lower layer of the solution. However, this purification method generally requires 2-3 rounds of repeated centrifugation to obtain relatively pure adenovirus particles, and it is difficult to achieve complete separation of the upper and lower layers. The yield of adenovirus obtained by this method is therefore low and very time consuming. Therefore, a purification scheme that can produce high-purity adenoviral vectors on a large scale is urgently needed.
Q-6XL阴离子交换层析法(AEX)是一种可放大的高效病毒载体纯化方案。腺病毒载体 的等电点低于7.4,在生理pH条件下带负电荷。与发酵液中的蛋白污染物相比,腺病毒对于阴离子交换层析柱的结合能力更强。而核酸类污染物的结合能力超过病毒,在层析过程中与病毒竞争结合位点。因此在后续采用不同的盐浓度进行洗脱,实现腺病毒的分离纯化。Q-6XL Anion Exchange Chromatography (AEX) is a scalable and efficient purification protocol for viral vectors. Adenoviral vectors have an isoelectric point below 7.4 and are negatively charged under physiological pH conditions. Compared with protein contaminants in fermentation broth, adenoviruses bind more strongly to anion exchange chromatography columns. The binding capacity of nucleic acid pollutants exceeds that of viruses, and competes with viruses for binding sites during the chromatography process. Therefore, different salt concentrations are used for subsequent elution to achieve separation and purification of adenovirus.
4FF凝胶过滤层析的分离范围为60KD-200MD,腺病毒分子约为700KD。在4FF层析过程中腺病毒与其他污染物分子量不同,从而导致分配系数不同,在层析过程中依次洗脱进而实现病毒纯化。并且层析过程中可直接进行溶液脱盐和除杂。但分子筛的普遍特性是非吸附性层析,负载量能力低,难以实现工业放大。本专利所选用的4FF是一款高偶联的 琼脂糖填料,机械强度大,能够解决腺病毒纯化工艺难以放大的瓶颈问题。因此选做病毒 纯化最后一步的精纯工艺。The separation range of 4FF gel filtration chromatography is 60KD-200MD, and the adenovirus molecule is about 700KD. During the 4FF chromatography process, the molecular weight of the adenovirus and other contaminants is different, resulting in different partition coefficients, and the virus is purified by successive elution during the chromatography process. Moreover, the solution desalting and impurity removal can be carried out directly during the chromatography process. However, the general characteristics of molecular sieves are non-adsorption chromatography, low loading capacity, and it is difficult to achieve industrial scale-up. The 4FF selected in this patent is a highly coupled agarose filler with high mechanical strength, which can solve the bottleneck problem that the adenovirus purification process is difficult to amplify. Therefore, it is selected as the purification process of the last step of virus purification.
发明内容SUMMARY OF THE INVENTION
本发明提出了一种基于Q-6XL和4FF串联的腺病毒规模化纯化方案。采用腺病毒感染的宿主细胞,培养48小时后形成病毒空斑,收获腺病毒发酵液。发酵液通过冻融、离 心、PEG(聚乙二醇)沉淀浓缩、置换缓冲液等工艺前处理后。首先通过Q-6XL阴离子交 换层析纯化得到腺病毒粗纯液、进一步采用4FF分子筛的层析方案精纯,最终得到高纯度 腺病毒载体。The present invention proposes a large-scale purification scheme of adenovirus based on the tandem of Q-6XL and 4FF. Adenovirus-infected host cells were used to form virus plaques after culturing for 48 hours, and the adenovirus fermentation broth was harvested. The fermentation broth is pre-treated by freezing and thawing, centrifugation, PEG (polyethylene glycol) precipitation and concentration, and buffer replacement. First, the crude adenovirus solution was obtained by purification by Q-6XL anion exchange chromatography, and further purified by the chromatographic scheme of 4FF molecular sieve, and finally a high-purity adenovirus vector was obtained.
本发明旨在建立一个能够大规模生产高纯度腺病毒的纯化工艺方案,主要分为以下几 个步骤:The present invention aims to establish a purification process scheme capable of large-scale production of high-purity adenovirus, which is mainly divided into the following steps:
(1)从细胞发酵液中将宿主细胞进行裂解,释放腺病毒载体;(1) lysing the host cell from the cell fermentation broth to release the adenovirus vector;
(2)通过离心从收获的细胞裂解液中去除细胞和细胞碎片,得到初步澄清的腺病毒 发酵液;(2) removing cells and cell debris from the harvested cell lysate by centrifugation to obtain a preliminary clarified adenovirus fermentation broth;
(3)采用PEG沉淀法浓缩发酵液;(3) adopt PEG precipitation method to concentrate fermentation broth;
(4)将发酵液置换到Q-6XL层析上样缓存液中;(4) replacing the fermentation broth into the Q-6XL chromatographic sample loading buffer;
(5)采用Q-6XL离子交换层析柱对腺病毒进行粗纯,得到腺病毒粗纯液;(5) using Q-6XL ion-exchange chromatography column to carry out crude purification of adenovirus to obtain a crude adenovirus solution;
(6)采用4FF分子筛对腺病毒粗纯液进行精纯,得到高纯度的腺病毒载体。(6) Purify the crude adenovirus liquid by using 4FF molecular sieve to obtain a high-purity adenovirus vector.
本发明将分别对每个部分进行详细说明:The present invention will describe each part in detail:
一、本发明提供的冻融法裂解宿主细胞的方法主要包括:1. The method for lysing host cells by freeze-thaw method provided by the present invention mainly includes:
1.本发明所述腺病毒在细胞内部、细胞培养上清液中均富集。收集全部病毒发酵液1. The adenovirus of the present invention is enriched both inside the cell and in the cell culture supernatant. Collect all virus fermentation broth
2.采用分批离心的方法,将上清液与细胞沉淀分离2. Use batch centrifugation to separate the supernatant from the cell pellet
3.将沉淀放于-80℃与25℃反复冻融3次,得到细胞裂解液3. Freeze and thaw the pellet at -80°C and 25°C for 3 times to obtain a cell lysate.
二、本发明提供的去除宿主细胞碎片的方法主要包括:2. The method for removing host cell debris provided by the present invention mainly includes:
1.对收获的细胞裂解液进行离心处理,只收集全部上清部分。1. Centrifuge the harvested cell lysate and collect only the entire supernatant fraction.
三、本发明提供的PEG沉淀浓缩、置换发酵液方法主要包括:Three, the PEG precipitation concentration provided by the invention, the replacement fermentation broth method mainly includes:
2.将PEG与腺病毒发酵液1:7(体积比)加入PEG溶液(500ml H20,500gPEG-8000)2. Add PEG and adenovirus fermentation broth 1:7 (volume ratio) to PEG solution (500ml H20, 500gPEG-8000)
3.加入10%(发酵液体积)的1M NaCl(氯化钠)(1L H20,58.5gNaCl)3. Add 10% (volume of fermentation broth) 1M NaCl (sodium chloride) (1L H20, 58.5gNaCl)
1.搅拌20min,4℃静置过夜1. Stir for 20min, let stand at 4℃ overnight
2.离心,去上清,层析上样缓冲液Buffer A重悬沉淀2. Centrifuge, remove the supernatant, and resuspend the pellet in the chromatographic loading buffer Buffer A.
四、本发明提供Q-6XL阴离子交换层析方法主要包括:Fourth, the present invention provides the Q-6XL anion exchange chromatography method mainly including:
1.用层析上样缓冲液Buffer A平衡Q-6XL,5-10CV(CV柱体积)1. Equilibrate Q-6XL with chromatography loading buffer Buffer A, 5-10CV (CV column volume)
2.上样(置换后的腺病毒发酵液),收集流穿液。2. Load the sample (substituted adenovirus fermentation broth) and collect the flow-through.
3.用层析上样缓冲液Buffer A清洗层析柱5-10CV3. Wash the column with chromatography loading buffer Buffer A for 5-10CV
4.30%层析上样洗脱液Buffer B洗脱5CV,收集洗脱液1。4. 30% chromatographic loading eluent Buffer B was eluted for 5 CV, and
5.50%层析上样洗脱液Buffer B洗脱5CV,收集洗脱液2(腺病毒粗纯液)5.50% chromatographic loading eluent Buffer B was eluted for 5CV, and the eluent 2 (crude adenovirus solution) was collected
五、本发明提供4FF阴离子交换层析方法主要包括:Five, the present invention provides 4FF anion exchange chromatography method mainly including:
1.用Buffer A平衡柱子2CV1. Equilibrate the column with Buffer A for 2CV
2.上样(第一步纯化收集到的洗脱液1)2. Loading (
3.洗脱2CV,收集各组份峰3. Elute 2CV and collect the peaks of each component
附图说明Description of drawings
图1:Q-6XL的分布梯度洗脱层析结果图Figure 1: Distribution gradient elution chromatography results of Q-6XL
图2:4FF层析结果图Figure 2: 4FF chromatographic results
图3:SDS-PAGE测定层析不同阶段料液中的蛋白含量Figure 3: Determination of protein content in feed solution at different stages of chromatography by SDS-PAGE
注:1:marker 2:离心后3:PEG沉淀浓缩置换后(10倍稀释) 4:蛋白峰 5:Q-6XL病毒粗纯峰 6:4FF后病毒峰Note: 1: marker 2: after centrifugation 3: after PEG precipitation concentration replacement (10-fold dilution) 4: protein peak 5: Q-6XL virus crude peak 6: virus peak after 4FF
具体实施方式Detailed ways
下面结合具体实例对本发明进行阐述The present invention will be described below in conjunction with specific examples
实施例1:Example 1:
采用本发明方法,基于Q-6XL和4FF两步法的腺病毒规模化纯化具体步骤包括:Adopting the method of the present invention, the specific steps of adenovirus large-scale purification based on the Q-6XL and 4FF two-step method include:
一、腺病毒前处理部分:1. Adenovirus pretreatment part:
1.采用HEK293-A宿主细胞培养腺病毒,接种48小时收获病毒发酵液3L。1. Use HEK293-A host cells to culture adenovirus, and harvest 3L of virus fermentation broth 48 hours after inoculation.
2.收获的病毒发酵液,4℃,3500rpm,离心15min。2. The harvested virus fermentation broth was centrifuged at 4°C, 3500rpm for 15min.
3.-80℃与25℃反复冻融3次,4℃,2000rpm,离心10min,收集上清液,共2.9L。3. Repeat freeze-thaw at -80°C and 25°C for 3 times, centrifuge at 4°C, 2000rpm for 10min, and collect the supernatant, a total of 2.9L.
4.PEG与腺病毒发酵液1:7(体积比)加入PEG溶液(500mlH20,500gPEG-8000)414ml,10%(发酵液体积)1M NaCL溶液(1L H20,58.5gNaCl)290ml。4. PEG and adenovirus fermentation broth were added in 1:7 (volume ratio) PEG solution (500ml H20, 500gPEG-8000) 414ml, 10% (fermentation broth volume) 1M NaCL solution (1L H20, 58.5gNaCl) 290ml.
5.搅拌20min,4℃静置8h-12h。5. Stir for 20 minutes, and stand at 4°C for 8h-12h.
6.4℃,8000rpm,离心40min,弃上清,用80mlQ-6XL层析上样缓冲液Buffer A重悬沉淀,并取样(置换后)。6.4°C, 8000rpm, centrifuged for 40min, discard the supernatant, resuspend the pellet with 80ml of Q-6XL chromatography loading buffer Buffer A, and sample (after replacement).
二、腺病毒纯化工艺:2. Adenovirus purification process:
1.Q-6XL所用缓冲液配置如下表:1. The buffer configuration used by Q-6XL is as follows:
层析缓冲液Buffer A、层析洗脱液Buffer B所涉及的Tris(三羟甲基氨基甲烷)为缓 冲成分、NaCl为洗脱成分、特别添加了5%(占所配Buffer A、B溶液体积)甘油作为 病毒保护剂成分、Buffer C所涉及的NaOH(氢氧化钠)为层析柱的清洗成分(保证层析 柱重复使用)、Buffer D所涉及的乙醇溶液为层析柱的储存成分。所用溶液均经过0.45μm 过滤后使用,溶液具体配比见下表:Chromatography buffer Buffer A and chromatographic eluent Buffer B involve Tris (tris(trihydroxymethylaminomethane)) as the buffer component, NaCl as the elution component, and specially added 5% (accounting for the prepared Buffer A and B solutions). Volume) glycerol is used as a virus protective agent component, NaOH (sodium hydroxide) involved in Buffer C is a cleaning component of the chromatography column (to ensure repeated use of the chromatography column), and the ethanol solution involved in Buffer D is a storage component of the chromatography column . The solutions used are all filtered at 0.45μm before use. The specific proportions of the solutions are shown in the following table:
4.Q-6XL的分布梯度洗脱实验流程4. The distribution gradient elution experiment process of Q-6XL
基于以上洗脱步骤,宿主蛋白和腺病毒实现了初步分离。层析结果图见附图1,在30% 层析洗脱液Buffer B下,宿主蛋白被洗脱,收集洗脱液1。50%层析洗脱液Buffer B下, 腺病毒被洗脱,收集洗脱液2(腺病毒粗纯液,Q-6XL后),宿主DNA完全结合在层析 柱中,清洗过程中洗脱。Based on the above elution steps, a preliminary separation of host protein and adenovirus was achieved. The chromatographic results are shown in Figure 1. Under the 30% chromatographic eluent Buffer B, the host protein was eluted, and the
5.4FF所用缓冲液配置同Q-6XL5.4FF uses the same buffer configuration as Q-6XL
6.4FF层析洗脱实验流程6.4 FF chromatographic elution experiment process
基于以上洗脱步骤,腺病毒发酵液实现了精纯,层析结果见附图2.病毒峰在洗脱溶液 条件下被洗脱。收集洗脱液3(腺病毒精纯液,4FF后)。Based on the above elution steps, the adenovirus fermentation broth was purified, and the chromatographic results were shown in accompanying
三、腺病毒纯化结果:3. Adenovirus purification results:
1.所有纯化步骤中,所收集的洗脱液分别为宿主蛋白、病毒粗纯液、病毒精纯液。采用Western-blot测定层析不同阶段料液中的蛋白含量,SDS-PAGE结果见附图3。1. In all purification steps, the collected eluates are host protein, virus crude liquid, and virus pure liquid. Western-blot was used to determine the protein content in the feed solution at different stages of the chromatography, and the SDS-PAGE results were shown in Figure 3.
2. 采用TCID50对各阶段病毒量进行测定,结果见表1。2. TCID50 was used to measure the amount of virus at each stage, and the results are shown in Table 1.
(1)准备96孔板,每孔接种8000个细胞,过夜培养,采用的细胞为HEK293A。(1) Prepare a 96-well plate, inoculate 8000 cells per well, and culture overnight. The cells used are HEK293A.
(2)腺病毒依次10倍稀释(梯度为10-3-10-10),充分混合。(2) The adenovirus was sequentially diluted 10 times (gradient of 10 -3 -10 -10 ), and mixed well.
(3)吸去96孔板中的培养基,并用PBS洗一次。(3) Aspirate the medium in the 96-well plate and wash once with PBS.
(4)每个浓度10重复接种腺病毒稀释液100μl,37℃,CO2培养箱培养。(4) 100 μl of adenovirus dilution solution was inoculated repeatedly at each concentration, and cultured in a CO2 incubator at 37°C.
(5)10天后,显微镜下观察细胞病变,记录病变孔。(5) After 10 days, the cytopathic changes were observed under a microscope, and the lesions were recorded.
表1.基于Q-6XL和4FF两步法的腺病毒纯化法回收率Table 1. Recovery of adenovirus purification method based on Q-6XL and 4FF two-step method
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010154302.XA CN111304176A (en) | 2020-03-07 | 2020-03-07 | A large-scale purification method of adenovirus vector based on Q-6XL and 4FF |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010154302.XA CN111304176A (en) | 2020-03-07 | 2020-03-07 | A large-scale purification method of adenovirus vector based on Q-6XL and 4FF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111304176A true CN111304176A (en) | 2020-06-19 |
Family
ID=71158534
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010154302.XA Pending CN111304176A (en) | 2020-03-07 | 2020-03-07 | A large-scale purification method of adenovirus vector based on Q-6XL and 4FF |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111304176A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112226418A (en) * | 2020-09-25 | 2021-01-15 | 阜外华中心血管病医院 | Recombinant adeno-associated virus purification method |
| CN114317464A (en) * | 2021-12-27 | 2022-04-12 | 武汉汇研生物科技股份有限公司 | Separation and purification method of adeno-associated virus rAAV9 |
| CN115627265A (en) * | 2022-10-27 | 2023-01-20 | 成都康华生物制品股份有限公司 | A kind of purification method of adenovirus |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1816620A (en) * | 2003-05-15 | 2006-08-09 | 因特罗根治疗公司 | Methods and compositions for producing adenoviral vectors |
| CN101235365A (en) * | 2007-01-31 | 2008-08-06 | 深圳市清华源兴生物医药科技有限公司 | Highly effective method for producing adenovirus |
| WO2017128783A1 (en) * | 2016-01-31 | 2017-08-03 | 中国人民解放军军事医学科学院生物工程研究所 | Ebola virus disease vaccine taking human replication deficient adenovirus as vector |
| CN107488637A (en) * | 2017-10-18 | 2017-12-19 | 成都远睿生物技术有限公司 | A kind of purification process of adenovirus |
| CN107603959A (en) * | 2017-08-30 | 2018-01-19 | 四川大学 | The method for improving buffer solution salt ionic concentration purified virus |
| CN107630037A (en) * | 2017-10-19 | 2018-01-26 | 和元生物技术(上海)股份有限公司 | A kind of purifying process for obtaining high-purity gland relevant viral vector |
| CN108531462A (en) * | 2018-04-20 | 2018-09-14 | 华南农业大学 | A kind of method of aviadenovirus consummateization |
| WO2019214110A1 (en) * | 2018-05-07 | 2019-11-14 | 中国人民解放军军事科学院军事医学研究院 | Marburg virus vaccine with human replication-deficient adenovirus as vector |
-
2020
- 2020-03-07 CN CN202010154302.XA patent/CN111304176A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1816620A (en) * | 2003-05-15 | 2006-08-09 | 因特罗根治疗公司 | Methods and compositions for producing adenoviral vectors |
| CN101235365A (en) * | 2007-01-31 | 2008-08-06 | 深圳市清华源兴生物医药科技有限公司 | Highly effective method for producing adenovirus |
| WO2017128783A1 (en) * | 2016-01-31 | 2017-08-03 | 中国人民解放军军事医学科学院生物工程研究所 | Ebola virus disease vaccine taking human replication deficient adenovirus as vector |
| CN107603959A (en) * | 2017-08-30 | 2018-01-19 | 四川大学 | The method for improving buffer solution salt ionic concentration purified virus |
| CN107488637A (en) * | 2017-10-18 | 2017-12-19 | 成都远睿生物技术有限公司 | A kind of purification process of adenovirus |
| CN107630037A (en) * | 2017-10-19 | 2018-01-26 | 和元生物技术(上海)股份有限公司 | A kind of purifying process for obtaining high-purity gland relevant viral vector |
| CN108531462A (en) * | 2018-04-20 | 2018-09-14 | 华南农业大学 | A kind of method of aviadenovirus consummateization |
| WO2019214110A1 (en) * | 2018-05-07 | 2019-11-14 | 中国人民解放军军事科学院军事医学研究院 | Marburg virus vaccine with human replication-deficient adenovirus as vector |
Non-Patent Citations (4)
| Title |
|---|
| MAFALDA G.MOLEIRINHO等: "Clinical-grade Oncolytic Adenovirus Purification using Polysorbate 20 as an Alternative for Cell Lysis", 《CURRENT GENE THERAPY》 * |
| MARC N.EGLON等: "Purification of adenoviral vectors by combined anion exchange and gel filtration chromatography", 《THE JOURNAL OF GENE MEDICINE》 * |
| 柴忠华: "H1/H5亚型流感重组腺病毒疫苗的制备工艺及安全性评价研究", 《中国优秀硕士学位论文全文数据库(电子期刊)医药卫生科技辑》 * |
| 郭海宁: "多亚型流感重组腺病毒疫苗生物反应器制备、纯化及免疫评价", 《中国优秀硕士学位论文全文数据库(电子期刊)医药卫生科技辑》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112226418A (en) * | 2020-09-25 | 2021-01-15 | 阜外华中心血管病医院 | Recombinant adeno-associated virus purification method |
| CN114317464A (en) * | 2021-12-27 | 2022-04-12 | 武汉汇研生物科技股份有限公司 | Separation and purification method of adeno-associated virus rAAV9 |
| CN115627265A (en) * | 2022-10-27 | 2023-01-20 | 成都康华生物制品股份有限公司 | A kind of purification method of adenovirus |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2134360B1 (en) | Virus like particle purification | |
| CN111304176A (en) | A large-scale purification method of adenovirus vector based on Q-6XL and 4FF | |
| CN111876393A (en) | Method for large-scale rapid production of high-purity high-activity lentiviral vector | |
| CN110241093A (en) | A kind of purification process of recombinant poxvirus | |
| CN101638427A (en) | Method for purifying virus antigens | |
| WO2024114733A1 (en) | Method for separating and purifying cvb1 | |
| CN108823245A (en) | A kind of purification process of virus-like particle | |
| JPH05508546A (en) | Purification of Erwinia-L-asparaginase | |
| JP7586936B2 (en) | Enhanced purification of adeno-associated virus to more effectively remove contaminating DNA | |
| CN113166732A (en) | Purification method for vaccine virus using affinity chromatography | |
| US20240035002A1 (en) | Method for purifying virus | |
| CN108611327A (en) | A kind of isolation and purification method of 2 porcine circovirus virus-like particle | |
| CN116769736B (en) | Production process for rapidly purifying lentivirus | |
| CN114106114B (en) | Method for purifying foot-and-mouth disease virus antigen by utilizing ion exchange chromatography | |
| CN111454914A (en) | Rapid adenovirus purification method | |
| CN118813560A (en) | A method for purifying adenovirus products and its application | |
| CN107603959A (en) | The method for improving buffer solution salt ionic concentration purified virus | |
| CN120290548B (en) | A method for purifying and preparing dsRNA standard | |
| CN103555682B (en) | The separation purification method of glucose oxidase | |
| CN102327608B (en) | Purifying method of encephalitis B vaccine | |
| CN107384878A (en) | A kind of method of consummate pig circular ring virus | |
| EP3871690A1 (en) | Method for virus production | |
| RU2745307C1 (en) | METHOD FOR PURIFICATION OF RECOMBINANT ADENOVIRUS 26 SEROTYPE (Ad26) | |
| CN119876120A (en) | Method for purifying plasmid DNA | |
| CN104130317B (en) | A kind of purification process of recombined hepatitis E hepatitis vaccine P179 antigen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20200619 |